The Federal Commission for the Protection against Sanitary Risks (Cofepris) reported that authorized the health registration of the drug Paxlovid (or ritonavir), from Pfizer. This is indicated for the treatment of COVID-19, in adults who are at risk of serious illness.
He explained that Paxlovid was evaluated by the Committee for New Molecules (CMN) and the rigorous technical analysis carried out by the agency’s specialized team.
The drug was found to meet the quality, safety and efficacy requirements, according to the information presented in the technical file.
”It is authorized open marketing of the first drug to prevent hospitalizations and mortality from COVID-19, with which Cofepris becomes one of the first regulatory agencies to authorize Paxlovid a health record of this type”, it was informed.
In which countries has Paxlovid been approved for use against COVID?
Paxlovid has already been approved by leading regulatory authorities such as the US Food and Drug Administration (FDA), Health Canada, and the European Medicines Agency (EMA).
In addition, the National Health Surveillance Agency of Brazil (Anvisa) and the National Medicines Agency of Chile (Anamed).
Where to buy Paxlovid in Mexico?
Paxlovid administration requires a prescriptionThe use and risk factors detailed in the authorization letter must be evaluated to avoid misuse, self-medication and irregular sales.
During the COVID-19 pandemic, Mexican health authorities prescribed the drug for specific cases and in a controlled manner.
COVID treatment can be prescribed for adults and adolescents aged 12 years and older.
What should we know about Paxlovid, a drug against COVID?
Treatment with Paxlovid should begin within the first five days after the onset of COVID-19 symptoms.
Paxlovid consists of two medicines: nirmatrelvir and ritonavir. The tablets are taken together twice a day for five days.
The tablets should be swallowed whole, that is, the patient should not chew, break or crush them. They can be taken on an empty stomach or with food.
Paxlovid should be given to people who are at risk of developing severe COVID that can lead to hospitalization or death.
